Stryker Corporation $SYK Shares Sold by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management Fondsmaeglerselskab A S cut its Stryker position by 42.6% in the fourth quarter, leaving it with 19,788 shares valued at about $6.96 million.
• Analysts remain broadly positive on SYK, with 16 Buy ratings and six Hold ratings; the consensus view is Moderate Buy and the average price target is $395.33.
• Stryker’s latest quarter missed expectations, with EPS of $2.60 versus $2.98 expected and revenue of $6.02 billion versus $6.34 billion expected, even as the company raised its FY2026 EPS guidance to 14.90–15.10.

BI Asset Management Fondsmaeglerselskab A S reduced its position in Stryker Corporation (NYSE:SYK - Free Report) by 42.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,788 shares of the medical technology company's stock after selling 14,709 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Stryker were worth $6,955,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. purchased a new stake in Stryker in the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the 3rd quarter worth $27,000. CGC Financial Services LLC purchased a new stake in shares of Stryker during the fourth quarter worth $29,000. Strive Asset Management LLC purchased a new stake in shares of Stryker during the third quarter worth $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Stryker during the third quarter worth $34,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SYK. UBS Group dropped their target price on shares of Stryker from $400.00 to $380.00 and set a "neutral" rating for the company in a report on Tuesday, March 17th. Citigroup dropped their target price on shares of Stryker from $420.00 to $385.00 and set a "buy" rating for the company in a report on Tuesday, April 7th. Evercore set a $355.00 target price on shares of Stryker in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, William Blair reaffirmed an "outperform" rating on shares of Stryker in a report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $395.33.

Stryker Trading Up 1.5%

Shares of SYK opened at $305.71 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The firm has a 50-day moving average price of $318.43 and a 200 day moving average price of $345.86. The firm has a market capitalization of $117.20 billion, a P/E ratio of 35.38, a P/E/G ratio of 1.93 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $6.34 billion. During the same period in the prior year, the company posted $2.84 EPS. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker's dividend payout ratio is currently 40.74%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company's stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.